TLR3 Knockout Immortalized Mouse Dendritic Cell Line

Unit

1×10⁶ cells / 1.0 ml

Cell Type

Stable (KO/Expressing) Cells

Tissue Type

Spleen

Organism

Mouse (M. musculus)

Donor History

TLR3 knockout CD11c:SV40LgT transgenic mice

Growth Properties

Adherent

,

small aggregates

Growth Conditions

Use of PriCoat™ T25 Flasks (G299) or Applied Cell Extracellular Matrix (G422) is recommended for cell adhesion to the culture vessels. Prigrow V (TM015) + 4 mM Glutamax + 10% heat-inactivated FBS + 1% of 7.5% Sodium Bicarbonate Solution + 50 µM beta-mercaptoethanol + 10 mM HEPES (TM058) + 1% Penicillin/Streptomycin Solution (G255)

,

37.0°C

,

5% CO₂. Filter the complete media with a 0.22µm filter prior to use. Change the complete media every 2-3 days. Do not let media colour change to yellow.

Immortalization Method
Full Information

https://www.abmgood.com/tlr3-knockout-immortalized-mouse-dendritic-cell-line.html

Katalogové číslo: T3034 Kategorie: ,
Popis

As messengers bridging the innate and adaptive immune system, the conventional tissue-resident DC (cDC) acts as sentinels in secondary lymphoid organs and other tissues for antigen capture and presentation. The MutuDCTlr3-/- cell line is an immortalized splenic CD8α subset (CD11chigh,B220-,DEC205 ,CD24high,CD11b-) of conventional dendritic cells derived from the TLR3 knockout CD11c:SV40LgT transgenic mice . The MutuDCTlr3-/- cell line retains response to TLR ligands such as CpG (TLR9-L) and to a lesser extent LPS (TLR4-L) but not PolyIC (TLR3-L). Like the Wild-type MutuDC cells (Cat. No. T0528), these cells are capable of presenting antigen in the context of both MHC-I and MHC-II, including direct antigen presentation and cross-presentation of cell-associated antigens. Together with TLR9 knockout (Cat. No. T3035) and Ifnar1 knockout (Cat. No. T3036) MutuDC, these dendritic cell lines provide a powerful tool in vaccine science and immunotherapy, particularly in strategizing target antigens to CD8α subset.

O značce
Applied Biological Materials (abm) je jedním z našich klíčových dodavatelů pro biotechnologický průmysl. Společnost byla založena v roce 2004 a již více než deset let podporuje vědecké objevy v oblasti přírodních věd a vývoje léčiv. Její sídlo se nachází ve Vancouveru v Kanadě. ABM je pro nás neocenitelným partnerem zejména v  oblasti dodávek buněčných kultur, genových a virových vektorů, produktů pro molekulární biologii a PCR, nástrojů pro technologie CRISPR a RNAi, protilátek i základních reagencií pro molekulárně genetické procesy.